Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Ships | 1 | 2020 | 1046 | 0.47 | Why? |
| Hong Kong | 7 | 2021 | 3361 | 0.28 | Why? |
| Ribavirin | 2 | 2020 | 1182 | 0.25 | Why? |
| Cross Reactions | 4 | 2021 | 4374 | 0.24 | Why? |
| Travel | 1 | 2020 | 7220 | 0.22 | Why? |
| Sf9 Cells | 4 | 2021 | 273 | 0.21 | Why? |
| Receptors, Antigen, B-Cell | 1 | 2021 | 424 | 0.18 | Why? |
| Interferon beta-1b | 1 | 2020 | 274 | 0.17 | Why? |
| Saliva | 4 | 2020 | 4679 | 0.16 | Why? |
| Herpes Zoster Vaccine | 1 | 2018 | 112 | 0.16 | Why? |
| Nasal Mucosa | 1 | 2003 | 1218 | 0.15 | Why? |
| Molecular Diagnostic Techniques | 3 | 2020 | 4239 | 0.15 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.15 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.14 | Why? |
| Epitopes | 3 | 2021 | 4113 | 0.13 | Why? |
| Intestines | 1 | 2020 | 817 | 0.13 | Why? |
| Organoids | 1 | 2020 | 840 | 0.13 | Why? |
| Herpes Zoster | 1 | 2018 | 331 | 0.12 | Why? |
| Betacoronavirus | 13 | 2020 | 204454 | 0.12 | Why? |
| Renal Replacement Therapy | 1 | 2021 | 1530 | 0.11 | Why? |
| Antibodies, Viral | 9 | 2021 | 51949 | 0.11 | Why? |
| Dendritic Cells | 1 | 2020 | 1330 | 0.11 | Why? |
| Protein Domains | 2 | 2021 | 6563 | 0.11 | Why? |
| Pneumonia, Viral | 13 | 2020 | 243684 | 0.11 | Why? |
| Coronavirus Infections | 13 | 2020 | 253789 | 0.11 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.11 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.10 | Why? |
| Severe Acute Respiratory Syndrome | 3 | 2020 | 12361 | 0.10 | Why? |
| Vero Cells | 6 | 2021 | 14117 | 0.10 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.10 | Why? |
| Communicable Diseases, Emerging | 1 | 2003 | 2523 | 0.09 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2020 | 13720 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Spike Glycoprotein, Coronavirus | 5 | 2021 | 37182 | 0.09 | Why? |
| Genome, Viral | 2 | 2020 | 13157 | 0.09 | Why? |
| Japan | 1 | 2020 | 6653 | 0.08 | Why? |
| Antibodies, Neutralizing | 7 | 2021 | 25288 | 0.08 | Why? |
| Antibody Formation | 1 | 2020 | 4038 | 0.08 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.08 | Why? |
| Genetic Variation | 1 | 2020 | 3919 | 0.08 | Why? |
| B-Lymphocytes | 1 | 2021 | 4418 | 0.08 | Why? |
| Viral Nonstructural Proteins | 2 | 2020 | 4810 | 0.07 | Why? |
| Mice, Inbred BALB C | 3 | 2021 | 5814 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.07 | Why? |
| Male | 18 | 2021 | 367725 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.06 | Why? |
| Neutralization Tests | 3 | 2021 | 6698 | 0.06 | Why? |
| Sensitivity and Specificity | 5 | 2020 | 22971 | 0.06 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.05 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2021 | 5762 | 0.05 | Why? |
| Female | 17 | 2021 | 380317 | 0.05 | Why? |
| Humans | 23 | 2021 | 930598 | 0.05 | Why? |
| Cells, Cultured | 2 | 2020 | 5835 | 0.05 | Why? |
| Animals | 7 | 2021 | 78931 | 0.05 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 3633 | 0.05 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Antigens | 1 | 2020 | 267 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2020 | 8207 | 0.04 | Why? |
| Aged | 11 | 2021 | 215776 | 0.04 | Why? |
| Enterocytes | 1 | 2020 | 245 | 0.04 | Why? |
| Adult | 11 | 2021 | 244371 | 0.04 | Why? |
| Mice | 3 | 2021 | 21357 | 0.04 | Why? |
| In Vitro Techniques | 1 | 2020 | 1027 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.04 | Why? |
| Mutation | 3 | 2021 | 12376 | 0.04 | Why? |
| Reference Standards | 1 | 2020 | 1163 | 0.04 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.04 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.04 | Why? |
| Cell Line | 2 | 2021 | 12040 | 0.04 | Why? |
| Glomerular Filtration Rate | 1 | 2021 | 1262 | 0.04 | Why? |
| Coronavirus | 1 | 2003 | 18339 | 0.03 | Why? |
| Protein Binding | 2 | 2021 | 11430 | 0.03 | Why? |
| Cell Differentiation | 1 | 2020 | 1338 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Pandemics | 14 | 2021 | 389249 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2020 | 11304 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Open Reading Frames | 1 | 2020 | 1898 | 0.03 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.03 | Why? |
| Intestinal Mucosa | 1 | 2020 | 1046 | 0.03 | Why? |
| Vaccines, Subunit | 1 | 2018 | 1088 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.03 | Why? |
| Viral Tropism | 1 | 2020 | 1329 | 0.03 | Why? |
| Respiratory Mucosa | 1 | 2020 | 1522 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2020 | 2290 | 0.03 | Why? |
| Single-Cell Analysis | 1 | 2021 | 2450 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Killer Cells, Natural | 1 | 2020 | 2093 | 0.03 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Convalescence | 1 | 2020 | 2829 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2003 | 9537 | 0.02 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.02 | Why? |
| Diabetes Complications | 1 | 2020 | 2358 | 0.02 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.02 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Chiroptera | 1 | 2020 | 3530 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Receptors, Virus | 1 | 2020 | 5659 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Phylogeny | 1 | 2021 | 13341 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.01 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
Tsang's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(138)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(193)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_